Baxter Reports Mixed Q1 2026 Results Amid Strategic Shifts — Baxter International Inc.

Event summary

Baxter reported Q1 2026 revenue of $2.7 billion, up 3% on a reported basis but down 1% organically.
Adjusted earnings per share from continuing operations fell 35% to $0.36 due to higher costs and unfavorable comparisons.
Medical Products & Therapies sales declined 2% organically, impacted by infusion pump shipment holds.
Pharmaceuticals segment grew 7% on a reported basis, driven by strong Drug Compounding performance.
Baxter reiterated its full-year 2026 outlook for flat to 1% reported sales growth and adjusted EPS of $1.85-$2.05.

The big picture

Baxter's Q1 results reflect ongoing challenges in integrating recent acquisitions and managing cost pressures while transitioning away from its divested Kidney Care business. The company is focusing on continuous improvement initiatives and product innovation to drive future growth, particularly in high-demand areas like Drug Compounding and Advanced Surgery products.

What we're watching

Execution Risk: Whether Baxter can stabilize its Medical Products & Therapies segment amid infusion pump challenges.
Cost Pressures: The impact of higher tariffs and manufacturing costs on Baxter's profitability moving forward.
Segment Performance: How the Pharmaceuticals segment can sustain its growth momentum in subsequent quarters.